Fact CheckerSign in

NCT07772544Not yet recruiting

Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

iPROLEPSIS-PPIDC: Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

Source: ClinicalTrials.gov · Last updated 16 Sept 2026

Brief summary (registry, in English)

This is an international, multicentre, feasibility mixed-methods, single-arm study evaluating the implementation of the iPROLEPSIS digital health promotion programme for adults with psoriatic arthritis (PsA) in real-world clinical practice. The study will enrol 72 adults with PsA (18 participants per country) across Portugal, the Netherlands, Greece, and the United Kingdom. Participants will be followed for 12 months, including a 1-month baseline monitoring period without intervention, followed by an 11-month intervention period during which participants will use the iPROLEPSIS digital health ecosystem. The iPROLEPSIS ecosystem integrates multiple digital health tools designed to support lifestyle management, self-monitoring, and patient engagement in PsA care. Participants will use the miPROLEPSIS app for active and passive data collection and personalised lifestyle recommendations related to diet and physical activity; biAURA for sleep and stress management using binaural beats; iPROLEPSIS Games to promote physical and emotional well-beingthrough serious games; and the miPROLEPSIS Joint Landmarker app for video-based functional assessments. The ecosystem will also integrate data from a Garmin vívoactive 5 smartwatch and wireless earbuds. Healthcare professionals involved in participant follow-up will access a dedicated clinical dashboard to support monitoring and clinical management. The primary objective of this feasibility study is to evaluate the usability of the iPROLEPSIS digital health ecosystem among patients with PsA and healthcare professionals using the System Usability Scale (SUS) and the eHealth UsaBility Benchmarking Instrument (HUBBI). Secondary objectives include assessing participant retention, acceptability of study participation, engagement with the digital health tools, adherence to study procedures, and identifying barriers and facilitators influencing the implementation of the digital health programme in routine clinical practice.The study will also generate preliminary evidence regarding potential changes in clinical and patient-reported outcomes associated with the use of the iPROLEPSIS ecosystem and include a preliminary budget impact analysis to inform the design of a future larger-scale clinical trial.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
72 (estimated)
First submitted
8 Aug 2026
Start date
Sept 2026
Primary completion date
Dec 2027
Lead sponsor
Sociedade Portuguesa de Reumatologia
NCT number
NCT07772544

What you commit to

  • Study type: Interventional
  • Planned participants: 72
  • From Sept 2026 to the primary completion date, Dec 2027
  • 4 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Illiteracy or inability to comply with the study protocol (e.g., due to hearing or visual impairments or significant cognitive impairment)

Other

  • Lack of access to the necessary technology to participate in the study (e.g., smartphone or stable internet connection)

Who the study is looking for

  • Willing and able to provide informed consent
  • Female or male, aged 18 years or older at the time of enrolment
  • Diagnosed with psoriatic arthritis
  • Had a rheumatology appointment in the past 12 months
  • Owns a smartphone (Android) compatible with the study apps
  • Willing to use the study smartwatch (Garmin Vivoactive 5) for the 12-month follow-up period
  • Proficient in the local language
  • Willing and able to provide informed consent
  • Involved in the clinical follow-up of PsA patients enrolled in the study

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hipokrateion Hospital Thessaloniki
Coordinator of this site? Confirm its status
ThessalonikiGreeceUnknown status
Unidade Local de Saúde de Aveiro, Serviço de Reumatologia, Hospital Infante Dom Pedro
Coordinator of this site? Confirm its status
AveiroPortugalUnknown status
Unidade Local de Saúde de São José, Serviço de Reumatologia, Hospital Santo António dos Capuchos
Coordinator of this site? Confirm its status
LisbonPortugalUnknown status
Unidade Local de Saúde de São João, Serviço de Reumatologia, Hospital São João
Coordinator of this site? Confirm its status
PortoPortugalUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.